What is Prolacta Bioscience?
Founded in 1999 and headquartered in Duarte, California, Prolacta Bioscience® Inc. is a privately held life sciences company dedicated to Advancing the Science of Human Milk®. Prolacta is recognized as the world's leading hospital provider of 100% human milk-based nutritional products. This focus positions the company at the forefront of neonatal nutrition, offering critical support for vulnerable infant populations. The company's commitment to scientific advancement in human milk utilization highlights its unique niche within the healthcare and biotechnology sectors.
How much funding has Prolacta Bioscience raised?
Prolacta Bioscience has raised a total of $73.6M across 6 funding rounds:
Series A
$811K
Series B
$5M
Series C
$12M
Private Equity
$5.8M
Series D
$15M
Private Equity
$35M
Series A (2004): $811K, investors not publicly disclosed
Series B (2006): $5M led by Arcturus Capital, Funk Ventures Capital, Gideon Hixon Fund, and Mercury Fund
Series C (2007): $12M supported by Funk Ventures, Alta Partners, DFJ Frontier, DFJ Mercury, and Gideon Hixon Fund
Private Equity (2011): $5.8M, investors not publicly disclosed
Series D (2011): $15M backed by Health Evolution Partners
Private Equity (2016): $35M, investors not publicly disclosed
Key Investors in Prolacta Bioscience
Funk Ventures
Funk Ventures is a multi-faceted private equity firm based in Los Angeles, California, with business segments spanning venture capital, investment banking, real estate, and business services. Their venture capital arm focuses on value-add investments in technology, interactive gaming, and wellness markets.
Alta Partners
Alta Partners is a venture capital firm specializing in healthcare and life sciences, supporting entrepreneurs in building impactful companies since 1996. They focus on innovative solutions that enhance patient outcomes and challenge existing healthcare paradigms.
DFJ Frontier
Frontier Venture Capital, operating in the Venture Capital & Private Equity industry, is headquartered in Boulder, Colorado. The firm focuses on identifying and investing in promising companies within its sector.
What's next for Prolacta Bioscience?
The recent major strategic investment signals a new phase of expansion and development for Prolacta Bioscience. This capital infusion is likely to fuel further research and development into advanced human milk-based therapies, enhance production capabilities, and broaden the company's reach within the hospital systems it serves. Prolacta's established leadership in neonatal nutrition, combined with this strategic backing, positions it for continued innovation and market leadership in the specialized field of infant nutrition.
See full Prolacta Bioscience company page
